Lantheus (LNTH) Proxy filing summary

Executive summary

• Annual Meeting scheduled for April 30, 2026, with both in-person and virtual attendance options.

• 2025 marked significant portfolio expansion, including acquisitions of Life Molecular Imaging and Evergreen Theragnostics, and divestiture of the legacy SPECT business.

• Leadership transition underway, with the Executive Chairperson also serving as interim CEO during the ongoing CEO search.

• Strategic focus sharpened on PET radiodiagnostics and late-stage pipeline advancement, with several regulatory milestones anticipated in 2026.

• Emphasis on disciplined execution, operational readiness, and targeted investment to support future growth.

Voting matters and shareholder proposals

• Election of four Class II directors for three-year terms.

• Advisory vote on executive compensation (“say on pay”) and on the frequency of future say-on-pay votes (Board recommends annual vote).

• Proposal to amend the Certificate of Incorporation to declassify the Board, transitioning to annual director elections by 2029.

• Approval of the Amended and Restated 2026 Equity Incentive Plan, increasing share reserve and updating director compensation limits.

• Ratification of Deloitte & Touche LLP as independent auditor for fiscal year 2026.

Board of directors and corporate governance

• Board consists of ten directors, nine of whom are independent; strong diversity with 50% women and broad industry expertise.

• Board committees (Audit, Nominating and Corporate Governance, Talent and Compensation, Science and Technology) are fully independent.

• Annual board and committee self-assessments guide governance enhancements and succession planning.

• Shareholder rights include proxy access, special meeting authority, and no poison pill.